Reach Us +1-217-403-9671
European Regulations In The Context Of Biosimilars | 8343
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

European regulations in the context of biosimilars

International Conference & Exhibition Bioequivalence and Bioavailability

Dr. Jean Louis Prugnaud

ScientificTracks Abstracts: J Bioequiv Availab 2010

DOI: 10.4172/0975-0851.1000001

T he drugs derived from biotechnology are now at a turning point in their relatively recent history. The extinction of patents protecting some innovative recombinant medicines introduced during the last two decades creates a new situation: manufacturers with the skills and technology needed to develop alternative products and to seek permission marketing. In this context, the European Medicines Agency (EMEA) has established a specific directive issued in 2004, which clarifies the definition of a biological drug similar to a biological drug reference and the content of the dossier to demonstrate equivalence of biotechnology drug [biosimilar] interchangeability with the original product. This legislation clearly distinguishable ?biosimilar drugs? from ?generic drugs?. While for generic drugs, the equivalence is taken for granted when the copy has the same quality and the same bioavailability than the original, biosimilars medicines must demonstrate comparability to the reference in terms of quality, safety and efficacy. Bioequivalence studies as for generics are not sufficient and the security of the biosimilar in comparison with the reference product should be assesses through specific pre-clinical and clinical trials. This demonstration is supplemented by a folder containing comprehensive quality and more studies comparability of the active substance and the finished product. The interchangeability is the major problem for physicians and pharmacists. The interchangeability is a therapeutic act comprising the knowledge of the patient and its story, the pathology, the indication, the dosage and the product complexity